Ribociclib Succinate
FDA-approved product (tablet, oral), marketed as Kisqali.
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Cyclin-dependent kinase (cdk) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ribociclib Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease46.2% AI-predicted activityagainst E. coli50+ registered studies
- Gilteritinib FumarateExisting use: Acute myeloid leukemia, Myeloid leukemia, Neoplasm46.2% AI-predicted activityagainst E. coli3 registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection46.2% AI-predicted activityagainst E. coli50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more46.2% AI-predicted activityagainst E. coli50+ registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma46.2% AI-predicted activityagainst E. coli50+ registered studies
- SelpercatinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more46.2% AI-predicted activityagainst E. coli42 registered studies
- Alectinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma46.1% AI-predicted activityagainst E. coli13 registered studies
- Neratinib MaleateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm46.1% AI-predicted activityagainst E. coli7 registered studies
- Leniolisib PhosphateExisting use: Inborn error of immunity46.0% AI-predicted activityagainst E. coliNo documented evidence found
- Quetiapine FumarateExisting use: Bipolar disorder, Bipolar I disorder, Bipolar II disorder and 4 more46.0% AI-predicted activityagainst E. coli50+ registered studies
- ZafirlukastExisting use: Airway obstruction, Asthma45.9% AI-predicted activityagainst E. coli6 registered studies
- CangrelorExisting use: Myocardial infarction, Percutaneous Coronary Intervention, Recurrent thrombophlebitis45.9% AI-predicted activityagainst E. coli45 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
NCT07391774 · start 2026-08-10
Registered record
- Registry ID
- NCT07391774
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma; HER2-Negative Breast Carcinoma
- Interventions
- Anastrozole; Biospecimen Collection; Bone Scan; Chemotherapy; Computed Tomography; Exemestane; Letrozole; Oncotype DX Breast Cancer Assay; Positron Emission Tomography; Ribociclib Succinate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2026-08-10
- Completion
- 2029-07-31
- Enrolment
- 1,978
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor-Positive Breast Carcinoma +1 moreInterventionAnastrozole; Biospecimen Collection; Bone Scan; Chemotherapy +6 morePhasePhase 3Registry statusRecruiting